101例结膜黑色素瘤的突变图谱与结局
该观察性病例系列对101例结膜黑色素瘤患者进行下一代测序、端粒替代延长(ALT)荧光原位杂交和ATRX免疫组化检测,记录2年和5年肿瘤相关转移与死亡结局。结果显示NF1(29/74,39%)、BRAF(31/101,31%)、NRAS(25/95,26%)和ATRX(17/68,25%)突变高频出现。NRAS突变与更高的2年转移率和死亡率相关,5年死亡风险约为野生型的5倍;ATRX突变与更低的2年转移率相关。
要点
- NF1、BRAF、NRAS和ATRX突变在结膜黑色素瘤中高频出现,ATRX突变常伴NF1突变。
- NRAS突变(vs NRAS野生型)与更高的2年转移率(28% vs 14%,P=0.07)和死亡率(16% vs 4%,P=0.04)相关。
- ATRX突变(vs ATRX野生型)与更低的2年转移率相关(0% vs 24%,P=0.005)。
核心结论
- 本研究证实结膜黑色素瘤中BRAF和NRAS突变高频存在,并发现近期报道的ATRX和NF1突变。
- NRAS突变提示转移和死亡风险增加。
- ATRX表达缺失和ALT可能是结膜黑色素瘤发生的早期事件。
研究设计与样本
- 观察性病例系列,纳入101例结膜黑色素瘤患者。
- 采用下一代测序(NGS)检测肿瘤突变谱,荧光原位杂交(FISH)检测端粒替代延长(ALT),并行ATRX免疫组化。
- 记录2年和5年肿瘤相关转移和死亡结局。
主要发现
- 101例患者中,就诊时平均年龄60岁,52%为男性,88%为白人。
- NGS检测发现高频突变:NF1(29/74,39%)、BRAF(31/101,31%)、NRAS(25/95,26%)、ATRX(17/68,25%)。
- ATRX突变者中12例(71%)伴有NF1突变。
- 21例黑色素瘤的子集分析显示,ATRX突变与ATRX蛋白表达缺失及ALT相关;ATRX表达缺失和ALT见于上皮内和侵袭性肿瘤。
- NF1和ATRX突变与睑板(vs 非睑板)肿瘤相关(NF1:28% vs 9%,P=0.035;ATRX:41% vs 14%,P=0.021),ATRX突变与眶内(vs 非眶内)肿瘤相关(24% vs 2%,P=0.007)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate targetable mutations and molecular genetic pathways in conjunctival melanoma with clinical correlation. DESIGN: Observational case series. PARTICIPANTS: Patients with conjunctival melanoma. MAIN OUTCOME MEASURES: Mutational profile of the tumor by next-generation sequencing (NGS), alternative lengthening of telomeres (ALT) by fluorescence in situ hybridization (FISH), and ATRX immunohistochemistry. Outcomes at 2 years and 5 years of tumor-related metastasis and death were recorded. RESULTS: Of the 101 patients, mean age at presentation was 60 years, 52% were male, and 88% were White. The NGS panels initially targeted BRAF only (n = 6, 6%), BRAF/NRAS (n = 17, 17%), and BRAF/NRAS/NF1 (n = 10, 10%). Sixty-eight tumors were tested with the expanded 592-gene panel. Next-generation sequencing identified high-frequency mutations in NF1 (29/74, 39%), BRAF (31/101, 31%), NRAS (25/95, 26%), and ATRX (17/68, 25%). Of those with an ATRX mutation, 12 (71%) had an additional NF1 mutation. A subset analysis of 21 melanomas showed that the ATRX mutation was associated with loss of ATRX protein expression and ALT. Loss of ATRX expression and ALT were present in both intraepithelial and invasive tumors, suggesting that an ATRX mutation is an early event in conjunctival melanoma progression. The NF1 and ATRX mutations were associated with tarsal (vs. nontarsal) tumors (NF1: 28% vs. 9%, P = 0.035, ATRX: 41% vs. 14%, P = 0.021) and orbital (vs. nonorbital) tumors (ATRX: 24% vs. 2%, P = 0.007). ATRXMUT (vs. ATRXWT) tumors were associated with a lower 2-year rate of metastasis (0% vs. 24%, P = 0.005). NRASMUT (vs. NRASWT) tumors were associated with a greater 2-year rate of metastasis (28% vs. 14%, P = 0.07) and death (16% vs. 4%, P = 0.04), with a 5-fold increased risk of death (relative risk, 5.45 [95% confidence interval, 1.11-26.71], P = 0.039). CONCLUSIONS: This study confirms the high frequency of previously documented BRAF and NRAS mutations and recently reported ATRX and NF1 mutations in conjunctival melanoma. An NRAS mutation implied increased risk for metastasis and death. Loss of ATRX and ALT may be early events in conjunctival melanoma development.
引用
- Lally SE, Milman T, Orloff M, et al. Mutational Landscape and Outcomes of Conjunctival Melanoma in 101 Patients. Ophthalmology. 2022. PMID: 35085662. doi:10.1016/j.ophtha.2022.01.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。